Bupropion for the Treatment of Methamphetamine Dependence - 1
- Conditions
- Amphetamine-Related Disorders
- Registration Number
- NCT00069251
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence
- Detailed Description
A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
- Subject must be willing to comply with study procedures.
- Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
- Be able to comply with protocol requirements
- Please contact site for more information.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Severity addiction Methamphetamine use
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Matrix Institute on Addictions
🇺🇸Costa Mesa, California, United States
South Bay Treatment Center
🇺🇸San Diego, California, United States
Pacific Addiction Research Center
🇺🇸Honolulu, Hawaii, United States
Powell Chemical Dependency Center
🇺🇸Des Moines, Iowa, United States
University of Missouri - Kansas City
🇺🇸Kansas City, Missouri, United States
Matrix Institute on Addictions🇺🇸Costa Mesa, California, United States